Imperial College London
Portrait Picture

ProfessorNagyHabib

Faculty of Medicine, Department of Surgery & Cancer

Professor of Hepatobiliary Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 8574nagy.habib

 
 
//

Assistant

 

Mrs Benita White +44 (0)7960 986 387

 
//

Location

 

BN1/18 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Giglio:2016:10.1245/s10434-016-5264-6,
author = {Giglio, MC and Giakoustidis, A and Draz, A and Jawad, ZAR and Pai, M and Habib, NA and Jiao, LR and Tait, P},
doi = {10.1245/s10434-016-5264-6},
journal = {Annals of Surgical Oncology},
pages = {3709--3717},
title = {Oncological outcomes of major liver resection following portal vein embolization: a systematic review and a meta-analysis},
url = {http://dx.doi.org/10.1245/s10434-016-5264-6},
volume = {23},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background Preoperative portal vein occlusion with either percutaneous portal vein embolization (PVE) or portal vein ligation (PVL) is routinely used to induce liver hypertrophy prior to major liver resection in patients with hepatic malignancy. While this increases the future liver remnant (FLR) and hence the number of patients suitable for resection, recent evidence suggests that induction of liver hypertrophy pre-operatively may promote tumour growth and increase recurrence rates.  Aim of the current study is to evaluate the impact of PVE on hepatic recurrence rate and survival in patients with colorectal liver metastases (CRLM).Methods Medline, Embase and Web of Science databases were searched to identify studies assessing the oncological outcomes of patients undergoing major liver resection for CRLM following PVE. Studies comparing patients undergoing one stage liver resection with or without pre-operative PVE were included. The primary outcome was hepatic recurrence (HR). Secondary outcomes were 3- and 5-year overall survival (OS). Results Of the 2131 studies identified, six nonrandomized studies (n=668) met the eligibility criteria comparing outcomes of patients undergoing major liver resection with or without PVE (n=182 vs. n=486 respectively). The median follow-up time ranged from 23.5 to 46 months. There was no significant difference in HR (OR, 0.78; 95% CI, 0.42 to 1.44, p=0.41), 3-year OS (OR, 0.80; 95% CI, 0.56 to 1.14, p=0.22) or 5-year OS (OR, 1.12; 95% CI, 0.40 to 3.11, p=0.82).    Conclusion PVE in patients with CRLM has no adverse effect on hepatic recurrence or overall survival following major liver resection.
AU  - Giglio,MC
AU  - Giakoustidis,A
AU  - Draz,A
AU  - Jawad,ZAR
AU  - Pai,M
AU  - Habib,NA
AU  - Jiao,LR
AU  - Tait,P
DO  - 10.1245/s10434-016-5264-6
EP  - 3717
PY  - 2016///
SN  - 1534-4681
SP  - 3709
TI  - Oncological outcomes of major liver resection following portal vein embolization: a systematic review and a meta-analysis
T2  - Annals of Surgical Oncology
UR  - http://dx.doi.org/10.1245/s10434-016-5264-6
UR  - http://hdl.handle.net/10044/1/31671
VL  - 23
ER  -
Download